The report of the 20th National Congress of the Communist Party of China pointed out that "we should adhere to the core position of innovation in China's overall modernization drive", "we should promote the deep integration of the innovation chain, industry chain, capital chain, talent chain", "we should open up new areas and new tracks for development, and constantly shape new drivers and new advantages for development". We attach great importance to scientific and technological work, face people's life and health, take biomedicine as an innovative industrial cluster, and gradually explore and form a "four in one" work promotion mechanism of "scientific and technological breakthrough+leading enterprises+major platforms+policy guidance". In 2021, the output value of the province's biopharmaceutical industry will account for about 1/8 of that of the whole country. 13 Jiayuan District will be included in the top 50 comprehensive competitiveness of the national biopharmaceutical industrial park, 12 enterprises will be included in the top 100 list of China's pharmaceutical industry, 4 enterprises will be included in the top 10 best industrial enterprises in China's pharmaceutical R&D product line, and Jiangsu's biopharmaceutical industry output value scale, R&D comprehensive strength, and product innovation level will all keep ahead of the country. We focus on strengthening the original and leading scientific and technological breakthrough of biomedicine. Integrate the advantages in the field of biomedicine inside and outside the province, integrate and implement the provincial science and technology plan projects, and achieve the full chain deployment of biomedicine innovation from drug discovery, preclinical research, clinical research to registration and listing. Since 2018, the provincial financial special projects have supported 944 biomedical projects, with a capital of more than 2.5 billion yuan. 26 innovative drugs have been approved, ranking first in the country. Enovirin Tablets of Jiangsu Aidi Pharmaceutical Co., Ltd. is the first oral class I new anti AIDS drug in China; Donaafinil Toluenesulfonate Tablets of Suzhou Zejing Biopharmaceutical Co., Ltd. is the first domestic first-line targeted drug for liver cancer on the market. We focus on cultivating bio pharmaceutical innovative enterprise clusters. Deeply implement the "Hundred Thousand" project of cultivating scientific and technological enterprises and the "Small Rise" action of high-tech enterprises, support leading backbone enterprises to take the lead in establishing bio pharmaceutical innovation consortia, promote the upstream and downstream of the industrial chain, large, small and medium-sized enterprises to jointly innovate, establish and improve the chain cultivation system from scientific and technological small and medium-sized enterprises to high-tech enterprises to innovative leading enterprises, and create a number of innovative leading enterprises with international competitiveness. At present, the number of high-tech enterprises in the biomedical field in Jiangsu Province has exceeded 1300, and the number of technology-based SMEs has reached 5670. The R&D investment of pharmaceutical enterprises above designated size accounts for about 7% of the main business income, nearly twice the average level of industrial enterprises above designated size. There are 46 A-share listed enterprises in the field of biomedicine, accounting for 10% of the country; The total market value is 824.5 billion yuan, accounting for 11.9% of the country. We strive to improve the major innovation platform system of biomedicine. Actively strive for the landing of the "national brand" platform, and successfully obtain the approval to build China's first technological innovation center in the field of biomedicine - the National Biomedical Technology Innovation Center. At present, a nucleic acid drug technology innovation platform and an organ like drug screening innovation platform have been established, and the list of the first batch of nuclear acid drug technology breakthrough projects has been released. Around drug screening
Edit：qihang Responsible editor：xinglan
Source：http://digitalpaper.stdaily.com/http_www.kjrb.com/kjrb/html/2022-11/02/content_543789.htm?div=-1
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
